{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:28:58Z","timestamp":1780392538153,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recurrent bacterial infection causes frequent bronchiectasis (BE) exacerbations. The effectiveness and safety of long-term administration of macrolides in BE remain controversial, especially in children who require minimal treatment to prevent exacerbation. We conducted this meta-analysis to determine the usefulness of long-term macrolide use in pediatric BE. We searched PubMed, Cochrane Library databases, Embase, KoreaMed, Igaku Chuo Zasshi, and Chinese National Knowledge Infrastructure databases. We identified randomized controlled trials (RCTs) which elucidated long-term macrolide treatment (\u2265\u20094\u00a0weeks) in non-cystic fibrosis BE in children aged\u2009&lt;\u200918\u00a0years. The primary outcome was frequency of acute exacerbation; secondary outcomes included changes in pulmonary function, sputum scores, and adverse events including bacterial resistance. We included four RCTs. Long-term macrolide treatment showed a significant decrease in the frequency of exacerbation (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.10\u20130.87), mean number of exacerbations per patient (mean difference, \u2212\u20091.40; 95% CI, \u2212\u20092.26 to \u2212\u20090.54), and sputum purulence score (mean difference, \u2212\u20090.78; 95% CI, \u2212\u20091.32 to \u2212\u20090.24). However, long-term macrolide treatment was accompanied by an increased carriage of azithromycin-resistant bacteria (OR, 7.13). Long-term macrolide administration prevents exacerbation of BE in children; however, there are risks of increasing antibiotic resistance. Benefits and risks should be weighed and determined on a patient-by-patient basis.<\/jats:p>","DOI":"10.1038\/s41598-021-03778-8","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T06:13:41Z","timestamp":1639980821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Eun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Suk","family":"Sol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Deok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Jong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taek Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwang Cheon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Ha","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Ju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong In","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwan Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Il","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungsu","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Hoon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"3778_CR1","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/14656566.2019.1589453","volume":"20","author":"E Lee","year":"2019","unstructured":"Lee, E. & Hong, S. J. Pharmacotherapeutic strategies for treating bronchiectasis in pediatric patients. Expert Opin. Pharmacother. 20, 1025\u20131036 (2019).","journal-title":"Expert Opin. Pharmacother."},{"key":"3778_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1164\/rccm.201906-1219OC","volume":"201","author":"KA Ramsey","year":"2020","unstructured":"Ramsey, K. A. et al. Airway mucus hyperconcentration in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 201, 661\u2013670 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3778_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.rmed.2019.01.018","volume":"150","author":"E Lee","year":"2019","unstructured":"Lee, E. et al. Clinical characteristics and etiologies of bronchiectasis in Korean children: A multicenter retrospective study. Respir. Med. 150, 8\u201314 (2019).","journal-title":"Respir. Med."},{"key":"3778_CR4","doi-asserted-by":"publisher","first-page":"105940","DOI":"10.1016\/j.rmed.2020.105940","volume":"166","author":"JS Imam","year":"2020","unstructured":"Imam, J. S. & Duarte, A. G. Non-CF bronchiectasis: Orphan disease no longer. Respir. Med. 166, 105940 (2020).","journal-title":"Respir. Med."},{"key":"3778_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/s12913-019-4414-5","volume":"19","author":"YG Lovie-Toon","year":"2019","unstructured":"Lovie-Toon, Y. G. et al. Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study. BMC Health Serv. Res. 19, 561 (2019).","journal-title":"BMC Health Serv. Res."},{"key":"3778_CR6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/thoraxjnl-2011-200206","volume":"67","author":"D Whitters","year":"2012","unstructured":"Whitters, D. & Stockley, R. Immunity and bacterial colonisation in bronchiectasis. Thorax 67, 1006\u20131013 (2012).","journal-title":"Thorax"},{"key":"3778_CR7","doi-asserted-by":"publisher","first-page":"636157","DOI":"10.1155\/2012\/636157","volume":"2012","author":"B Kwiatkowska","year":"2012","unstructured":"Kwiatkowska, B. & Maslinska, M. Macrolide therapy in chronic inflammatory diseases. Mediators Inflamm. 2012, 636157 (2012).","journal-title":"Mediators Inflamm."},{"key":"3778_CR8","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2013.1937","volume":"309","author":"J Altenburg","year":"2013","unstructured":"Altenburg, J. et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. JAMA 309, 1251\u20131259 (2013).","journal-title":"JAMA"},{"key":"3778_CR9","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J. P. et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).","journal-title":"BMJ"},{"key":"3778_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem, H. et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 64, 401\u20136 (2011).","journal-title":"J. Clin. Epidemiol."},{"key":"3778_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1183\/09031936.97.10050994","volume":"10","author":"YY Koh","year":"1997","unstructured":"Koh, Y. Y., Lee, M. H., Sun, Y. H., Sung, K. W. & Chae, J. H. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: A double-blind, placebo-controlled study. Eur. Respir. J. 10, 994\u2013999 (1997).","journal-title":"Eur. Respir. J."},{"key":"3778_CR12","first-page":"044","volume":"5","author":"R Masekela","year":"2013","unstructured":"Masekela, R. et al. Lack of efficacy of an immunomodulatory macrolide in childhood HIV related bronchiectasis: A randomised, placebo-controlled trial. J. Antivir. Antiretrovir. 5, 044\u2013049 (2013).","journal-title":"J. Antivir. Antiretrovir."},{"key":"3778_CR13","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S2213-2600(13)70185-1","volume":"1","author":"PC Valery","year":"2013","unstructured":"Valery, P. C. et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): A multicentre, double-blind, randomised controlled trial. Lancet Respir. Med. 1, 610\u2013620 (2013).","journal-title":"Lancet Respir. Med."},{"key":"3778_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2710.2006.00708.x","volume":"31","author":"E Yalcin","year":"2006","unstructured":"Yalcin, E. et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J. Clin. Pharm. Ther. 31, 49\u201355 (2006).","journal-title":"J. Clin. Pharm. Ther."},{"key":"3778_CR15","doi-asserted-by":"publisher","first-page":"106209","DOI":"10.1016\/j.rmed.2020.106209","volume":"175","author":"E Lee","year":"2020","unstructured":"Lee, E. & Lee, Y. Y. Risk factors for the development of post-infectious bronchiolitis obliterans after Mycoplasma pneumoniae pneumonia in the era of increasing macrolide resistance. Respir. Med. 175, 106209 (2020).","journal-title":"Respir. Med."},{"key":"3778_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3345\/kjp.2017.60.5.151","volume":"60","author":"E Lee","year":"2017","unstructured":"Lee, E. et al. Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children. Korean J. Pediatr. 60, 151\u2013157 (2017).","journal-title":"Korean J. Pediatr."},{"key":"3778_CR17","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","volume":"366","author":"WA Ray","year":"2012","unstructured":"Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G. & Stein, C. M. Azithromycin and the risk of cardiovascular death. N. Engl. J. Med. 366, 1881\u20131890 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3778_CR18","doi-asserted-by":"publisher","first-page":"e15285","DOI":"10.1097\/MD.0000000000015285","volume":"98","author":"D Wang","year":"2019","unstructured":"Wang, D., Fu, W. & Dai, J. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis. Medicine (Baltimore) 98, e15285 (2019).","journal-title":"Medicine (Baltimore)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03778-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03778-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03778-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:21:55Z","timestamp":1670073715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03778-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3778"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03778-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-577493\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24287"}}